Repositorio Dspace

New landscape of the diagnosis of Alzheimer's disease

Mostrar el registro sencillo del ítem

dc.contributor.author Frisoni, Giovanni B.
dc.contributor.author Hansson, Oskar
dc.contributor.author Nichols, Emma
dc.contributor.author Garibotto, Valentina
dc.contributor.author Schindler, Suzanne E.
dc.contributor.author van der Flier, Wiesje M.
dc.contributor.author Jessen, Frank
dc.contributor.author Villain, Nicolas
dc.contributor.author Arenaza-Urquijo, Eider M.
dc.contributor.author Crivelli, Lucia
dc.contributor.author Fortea, Juan
dc.contributor.author Grinberg, Lea T.
dc.contributor.author Ismail, Zahinoor
dc.contributor.author Minoshima, Satoshi
dc.contributor.author Ossenkoppele, Rik
dc.contributor.author Zetterberg, Henrik
dc.contributor.author Petersen, Ronald C.
dc.contributor.author Dubois, Bruno
dc.date.accessioned 2025-10-21T15:52:12Z
dc.date.available 2025-10-21T15:52:12Z
dc.date.issued 2025-09-22
dc.identifier.citation Frisoni GB, Hansson O, Nichols E, Garibotto V, Schindler SE, van der Flier WM, et al. New landscape of the diagnosis of Alzheimer’s disease. Lancet. 27 de septiembre de 2025;406(10510):1389-407 es_ES
dc.identifier.uri https://doi.org/10.1016/S0140-6736(25)01294-2
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1417
dc.description.abstract Alzheimer's disease involves a drastic departure from the cognitive, functional, and behavioural trajectory of normal ageing, and is both a dreaded and highly prevalent cause of disability to individuals, and a leading source of health and social care expenditure for society. Before the advent of biomarkers, post-mortem examination was the only method available to establish a definitive diagnosis. In this first paper of the Series, we review state-of-the-art diagnostic practices and the typical patient journey in specialist settings, where clinicians engage in a differential diagnosis to establish whether Alzheimer's pathology (cerebral deposition of β-amyloid and hyperphosphorylated tau) is a contributor to cognitive impairment. Biomarkers indicating dysregulation of β-amyloid and tau homeostasis, measured with PET and cerebrospinal fluid analysis, allow a molecular-level diagnosis-a mandatory step in defining eligibility for the recently approved anti-amyloid treatments. We anticipate that easily accessible blood biomarkers, already available in some countries, will lead to a new diagnostic revolution and bring about major changes in health-care systems worldwide. es_ES
dc.language.iso eng es_ES
dc.publisher Elsevier es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.subject Alzheimer Disease es_ES
dc.subject Enfermedad de Alzheimer es_ES
dc.subject Amyloid beta-Peptides es_ES
dc.subject Péptidos beta-Amiloides es_ES
dc.subject Biomarkers es_ES
dc.subject Biomarcadores es_ES
dc.subject Diagnosis, Differential es_ES
dc.subject Diagnóstico Diferencial es_ES
dc.subject Positron-Emission Tomography es_ES
dc.subject Tomografía de Emisión de Positrones es_ES
dc.subject tau Proteins es_ES
dc.subject Proteínas tau es_ES
dc.title New landscape of the diagnosis of Alzheimer's disease es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Crivelli, Lucía. Fleni. Departamento de Neurología. Servicio de Neurología Cognitiva, Neuropsicología y Neuropsiquiatría; Argentina.
dc.relation.ispartofVOLUME 406
dc.relation.ispartofNUMBER 10510
dc.relation.ispartofPAGINATION 1389-1407
dc.relation.ispartofCOUNTRY Reino Unido
dc.relation.ispartofCITY Londres
dc.relation.ispartofTITLE Lancet
dc.relation.ispartofISSN 1474-547X
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Buscar en DSpace


Listar

Mi cuenta

Estadísticas